Cord Blood Stem Cells Medicine (eBook)

Dominique Charron, Cristina Navarrete, Catherine Stavropoulos-Giokas (Herausgeber)

eBook Download: PDF | EPUB

2014 | 1. Auflage
398 Seiten
Elsevier Science (Verlag)
978-0-12-407836-9 (ISBN)

Infos

Cord Blood Stem Cells and Regenerative Medicine discusses the current applications for cord blood stem cells and techniques for banking cord blood. Cord blood, blood from the umbilical cord and placenta of an infant, represents an alternate source of stem cells that can be used to treat a myriad of disorders. Cord blood stem cells are being used more frequently and studied more seriously, as evidenced by the explosion of scientific literature on the topic.

Currently, clinical and pre-clinical trials are being done in the field, treating conditions as severe as heart failure. Coupled with regenerative medicine, cord blood stem cells potentially carry the future of research and medicine in treating tissue damage, genetic disorders, and degenerative diseases. Read about new applications for cord blood stem cells and new techniques for banking cord blood - the future of regenerative medicine therapy.

• Comprehensive coverage of the medical application of cord blood stem cells
• Practical guide for usage of allogeneic and autologous cord blood in regenerative medicine
• Covers new applications of cord blood stem cells, particularly transplantation and HIV
• Introduces new technologies for cord blood stem cells and regenerative medicine

Inhalt

Front 
1 
Cord Blood Stem 
4 
Copyright 5
Contents 6
List of Contributors 14
Foreword 18
TWENTY-FIVE YEARS OF CORD BLOOD TRANSPLANT 18
Section I - 
20 
Chapter 1 - Introduction to Cord Blood Stem Cells 22
Section II - 
26 
Chapter 2 - Cord Blood Content 28
1. BIOLOGICAL BACKGROUND OF CORD BLOOD CELLS—DEVELOPMENT OF HEMATOPOIETIC AND NONHEMATOPOIETIC CELLS 28
2. ENDOTHELIAL CELLS IN CB 28
3. STROMAL CELLS IN CB AND CORD TISSUE AS COMPARED TO BM 29
4. ISOLATION, EXPANSION, AND CHARACTERIZATION OF CB-DERIVED ADHERENT CELLS FROM CB 31
5. GENERATION OF CELL CLONES AND CLONAL POPULATIONS 31
6. USSC AND CB MSC 31
7. GENERATION OF ADHERENT CELLS FROM THE WHARTON’S JELLY (CORD) 31
8. GENE EXPRESSION PROFILES 32
9. CORRELATION OF HOX-GENE EXPRESSION AND REGENERATIVE POTENTIAL 32
10. BONE AND CARTILAGE FORMING POTENTIAL OF CORD BLOOD STROMAL CELLS 35
11. WHY DO WE HAVE THESE PROGENITORS OR ELUSIVE CELLS IN CB? 35
12. USSC AND MSC FROM CB SUPPORT HEMATOPOIETIC CELLS 36
13. LIVER REGENERATION AND POTENTIAL OF CB-DERIVED STEM CELLS TO UNDERGO HEPATIC DIFFERENTIATION 39
14. CARDIAL REGENERATION IN VIVO 40
15. IN VITRO DIFFERENTIATION POTENTIAL TOWARD CARDIOMYOCYTES 40
16. CB SUBPOPULATIONS FOR NEURONAL REGENERATION 41
17. REPROGRAMMED SUBPOPULATIONS FROM CB 41
18. CONCLUSION 42
LIST OF ACRONYMS AND ABBREVIATIONS 42
REFERENCES 43
Chapter 3 - Cord Blood Hematopoiesis: The Road to Transplantation 46
1. USE OF PLACENTAL CORD BLOOD AS A SOURCE FOR HEMATOPOIETIC STEM/PROGENITOR CELLS TRANSPLANTATION: A HISTORICAL.PERSPECTIVE 46
2. CHARACTERIZATION OF PCB HSPCS 47
3. STRATEGIES TO OVERCOME CURRENT LIMITATIONS IN PCB TRANSPLANTATION 48
4. INCREASING THE HSPCS OF THE GRAFT 49
5. IMPROVING THE LODGING CAPACITY OF THE PCB GRAFT 52
6. IMPROVING THE STEM CELL RECEPTIVITY OR IMMUNOLOGICAL.STATUS OF THE HOST 53
7. ADDITIONAL CLINICAL USES OF CORD BLOOD UNDER INVESTIGATION 53
8. CONCLUDING REMARKS 53
REFERENCES 54
Chapter 4 - Immunobiology of Cord Blood Cells 58
1. INTRODUCTION 58
2. IMMUNE PROPERTIES OF CORD BLOOD CELLS 58
3. IMMUNE RECONSTITUTION AFTER CBT 60
4. GENERATION OF IMMUNE COMPETENT CELLS FROM CORD BLOOD 61
5. CONCLUSION 64
LIST OF ABBREVIATIONS 64
REFERENCES 64
Chapter 5 - Cord and Cord Blood-derived Endothelial Cells 68
1. INTRODUCTION 68
2. THE HUMAN ENDOTHELIAL COLONY-FORMING CELL HIERARCHY 70
3. DIFFERENCES BETWEEN HUMAN UMBILICAL CORD BLOOD.ECFCS AND THOSE SOURCED FROM ADULT PERIPHERAL.BLOOD, UMBILICAL CORD, AND PLACE... 70
4. OBSTETRIC FACTORS AND ECFC CONTENT IN UMBILICAL.CORD BLOOD AT TERM 71
5. ECFC CONTENT AND FUNCTION IN UMBILICAL CORD.BLOOD BASED ON GESTATIONAL AGE 72
6. THE DIABETIC ENVIRONMENT AFFECTS UMBILICAL CORD.BLOOD ECFCS 73
7. PROCESSING AND CRYOPRESERVATION AFFECT ECFC.NUMBERS IN UMBILICAL CORD BLOOD 74
8. THE PHENOTYPIC IDENTITY OF ECFCS 74
9. THE USE OF UMBILICAL CORD BLOOD OR PLACENTAL ECFCS.AS A CELLULAR PRODUCT IN REGENERATIVE MEDICINE 76
10. CONCLUSIONS 76
LIST OF ACRONYMS AND ABBREVIATIONS 77
ACKNOWLEDGMENT 77
REFERENCES 77
Chapter 6 - HLA and Immunogenetics in Cord Blood Transplantation 82
1. INTRODUCTION 82
2. STRUCTURE, FUNCTION, AND POLYMORPHISM OF HLA 83
3. HLA TYPING TECHNIQUES 83
4. CBT RESULTS 85
5. OTHER HLA CRITERIA FOR CBU SELECTION 88
6. CONCLUSION 90
LIST OF ABBREVIATIONS 90
REFERENCES 91
Section III - 
94 
Chapter 7 - Clinical Use of Umbilical Cord Blood Cells 96
1. INTRODUCTION 96
2. CLINICAL CB TRANSPLANTATION 97
3. CLINICAL USE OF RELATED CB CELLS FOR ALLOGENEIC TRANSPLANTATION 98
4. CLINICAL USE OF UNRELATED CB CELLS FOR ALLOGENEIC TRANSPLANTATION 99
5. SELECTION OF CB UNITS FOR TRANSPLANTATION 107
6. NEW STRATEGIES TO IMPROVE OUTCOMES AFTER CB TRANSPLANTATION 112
7. CONCLUSION 115
LIST OF ACRONYMS AND ABBREVIATIONS 115
REFERENCES 116
Chapter 8 - Immunodeficiencies and Metabolic Diseases 120
1. IMMUNODEFICIENCIES 120
2. METABOLIC DISEASES 123
REFERENCES 127
Chapter 9 - Cord Blood Cells and Autoimmune Diseases 132
1. INTRODUCTION 132
2. NEW INSIGHTS IN THE PATHOGENESIS OF ADS 133
3. HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF AD 134
4. USE OF UCB-DERIVED CELLS AND CORD BLOOD MSCS FOR TREATING AD 135
5. CONCLUSION 139
REFERENCES 139
Chapter 10 - Umbilical Cord as a Source of Immunomodulatory Reagents 144
1. REGULATORY T-CELLS 144
2. MESENCHYMAL STROMAL CELLS 149
3. CONCLUSIONS 152
REFERENCES 152
Chapter 11 - Cord Blood Cells for Clinical Use: Expansion and Manipulation 160
1. INTRODUCTION 160
2. CB TRANSPLANTATION IN PEDIATRIC PATIENTS 161
3. CB TRANSPLANTATION IN ADULT PATIENTS 162
4. DOUBLE CB TRANSPLANTATION 163
5. CB TRANSPLANTATION AFTER REDUCED INTENSITY REGIMENS 164
6. CB GRAFT MANIPULATION 164
7. CB STEM CELL AND PROGENITOR CELL EXPANSION TO ENHANCE ENGRAFTMENT 164
8. IMPROVING CB HOMING TO BM 165
9. PROSTAGLANDIN AND HOMING 166
10. CB IMMUNE CELLS TO IMPROVE OUTCOME 166
11. EXPANDING MULTIVIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES FROM CB 166
12. CB-DERIVED NATURAL KILLER (NK) CELLS 167
13. CB-DERIVED REGULATORY T CELLS 167
14. REDIRECTING SPECIFICITY OF CB-DERIVED T CELLS TO LEUKEMIA ANTIGENS 167
15. CONCLUSION 167
REFERENCES 168
Chapter 12 - Cord Blood Stem Cells for Clinical Use: Diabetes and Cord Blood 172
1. DIABETES AND GLOBAL CHALLENGES 172
2. STEM CELLS IN CORD BLOOD 175
3. APPLICATION OF STEM CELL EDUCATOR THERAPY IN T1D 176
4. APPLICATION OF STEM CELL EDUCATOR THERAPY IN TYPE 2 DIABETES 178
5. CONCLUSIONS 181
DR YONG ZHAO’S BIBLIOGRAPHY 181
REFERENCES 181
Section IV - 
 
184 
Chapter 13 - Emerging Uses of Cord Blood in Regenerative Medicine—Neurological Applications 186
1. INTRODUCTION 186
2. UMBILICAL CB AS A SOURCE OF STEM CELLS FOR NEUROLOGICAL APPLICATIONS 186
3. POTENTIAL MECHANISMS OF CB AS THERAPY FOR PATIENTS WITH NEUROLOGICAL DISEASES 187
4. UNRELATED DONOR CB TRANSPLANTATION FOR GENETIC BRAIN DISEASES IN CHILDREN 187
5. ISCHEMIC INJURIES 189
6. NEURODEGENERATIVE DISEASES 192
7. AUTISM 192
8. CHALLENGES 193
9. SUMMARY 193
REFERENCES 193
Chapter 14 - Biobanks for Induced Pluripotent Stem Cells and Reprogrammed Tissues 198
1. INTRODUCTION: A BRIEF HISTORY OF INDUCED PLURIPOTENCY 198
2. WHAT DEFINES PLURIPOTENCY AND THE PLURIPOTENT STEM CELL 199
3. REPROGRAMMING HUMAN SOMATIC CELLS TOWARD INDUCED PLURIPOTENT STEM CELLS USING DEFINED FACTORS 200
4. TISSUE DIFFERENTIATION FROM HIPSCS 203
5. POTENTIAL APPLICATIONS FOR HIPSCS IN FUTURE REGENERATIVE MEDICINES 205
6. CONSIDERATIONS TOWARD DEVELOPMENT OF HIPSC-DERIVED THERAPIES 207
7. FINAL CONSIDERATIONS 209
ACKNOWLEDGMENT 209
REFERENCES 209
Section V - 
 
214 
Chapter 15 - Cord Blood Banking: Operational and Regulatory Aspects 216
1. INTRODUCTION 216
2. CONCLUSIONS 225
REFERENCES 226
Chapter 16 - Cord Blood Unit Selection for Unrelated Transplantation 230
1. OVERVIEW: SEARCH AND CORD BLOOD UNIT SELECTION 230
2. QUALITY/POTENCY OF THE CBU 231
3. SELECTION OF CB UNITS FOR TRANSPLANT: INTERACTION OF TNC AND HLA 232
4. SELECTION OF CBU WITH “PERMISSIBLE” HLA MISMATCHES 234
5. APPROACHES TO OVERCOME THE TNC LIMITATIONS OF SINGLE CB GRAFTS 237
6. QUALITY OF CBU—BANKING PRACTICES 238
7. PATIENT DIAGNOSIS, RELAPSE RISK, AND CBU SELECTION 239
8. OTHER IMMUNOLOGICAL CONSIDERATIONS FOR CBU SELECTION 240
9. OTHER GRAFT CHARACTERISTICS AFFECTING CBU QUALITY AND SAFETY 241
10. “BACK-UP” CB GRAFTS 243
11. CONCLUSIONS—SELECTION GUIDELINES 243
ACKNOWLEDGMENT 244
REFERENCES 244
Chapter 17 - Quality Management Systems Including Accreditation Standards 248
1. INTRODUCTION 249
2. QUALITY MANAGEMENT 249
3. QM SYSTEMS 251
4. CREATING A DOCUMENTED QUALITY MANAGEMENT SYSTEM (PROGRAM): QUALITY MANAGEMENT PLAN 256
5. STANDARDIZED SYSTEMS 263
6. ACCREDITATION 264
7. CONCLUSION 266
ABBREVIATIONS 266
REFERENCES 266
Chapter 18 - Regulation Across the Globe 268
1. INTRODUCTION 268
2. REGULATION IN THE EU 269
3. CORD BLOOD BANKING IN THE USA 273
4. CORD BLOOD BANKING IN ASIA, AFRICA, AND OCEANIA 276
5. CONCLUSION 278
REFERENCES 278
Chapter 19 - International Development and Import/Export—WMDA 280
1. INTRODUCTION 280
2. ISSUES TO CONSIDER WHEN STARTING A CORD BLOOD BANK 281
3. LISTING OF CORD BLOOD UNITS—MAKING THEM AVAILABLE TO TRANSPLANT UNITS 283
4. REGISTRY—GATEWAY TO THE WORLD 284
5. SEARCH FOR CORD BLOOD 287
6. CHALLENGES RELATED TO THE PROVISION OF CORD BLOOD—SELECTION 291
7. CHALLENGES RELATED TO THE PROVISION OF CORD BLOOD—SERVICE PROVIDER 292
8. CHALLENGES RELATED TO THE PROVISION OF CORD BLOOD—REGULATION 293
9. CORD BLOOD BANKS WORLDWIDE 296
10. ANALYZING THE FIELD—NUMBER OF CORD BLOOD SHIPMENTS 297
11. FUTURE PLANS FOR CORD BLOOD BANKS 298
12. LIST OF CORD BLOOD REGISTRIES/BANKS 299
REFERENCES 300
Section VI - 
 
302 
Chapter 20 - Allogeneic and Autologous Cord Blood Banks 304
1. A “PERFECT” MATCH? 304
2. STEM CELL TRANS-DIFFERENTIATION AND TISSUE REPAIR? 304
3. SOURCE AND QUALITY OF INFORMATION 305
4. MATERNAL AND PATERNAL KNOWLEDGE AND PREFERENCES 306
5. CONCLUSIONS: WHAT IS THE CURRENT “CHILD’S BEST INTEREST”? 307
CONFLICT OF INTEREST 307
REFERENCES 307
Chapter 21 - The Future of Cord Blood Banks 310
1. INTRODUCTION 310
2. CB AND FETAL ANNEX TISSUES ARE AN ABUNDANT SOURCE OF “YOUNG” STEM CELLS 311
3. CB-DERIVED EPCS 311
4. UC WHARTON’S JELLY MSCS 314
5. THE IPSCS 317
6. CB AND UC COMPONENTS 320
7. CONCLUSION 321
LIST OF ABBREVIATIONS 322
REFERENCES 322
Section VII - 
328 
Chapter 22 - An Introductory Note to the Cord Blood Banking Issues in a European and International Environment 330
Chapter 23 - Ethical and Legal Issues in Cord Blood Stem Cells and Biobanking 332
1. INTRODUCTION 332
2. SCIENTIFIC BACKGROUND: STEM CELLS FROM CORD BLOOD, THE UMBILICAL CORD, AND THE PLACENTA 333
3. FUNDAMENTAL ETHICAL AND LEGAL ISSUES 334
4. THE STATUS OF THE UMBILICAL CORD AND THE PLACENTA 334
5. LEGISLATIVE CHARACTERIZATIONS OF STEM CELLS FROM CORD BLOOD, THE UMBILICAL CORD, AND THE PLACENTA 335
6. INFORMED CONSENT 336
7. COMMUNICATION OF INFORMATION TO THE DONOR OF CORD BLOOD, UMBILICAL CORD, AND PLACENTA REGARDING LIKELY DISEASES 337
8. THE DONATION OF CORD BLOOD, UMBILICAL CORD, AND PLACENTA AND NONCOMMERCIALIZATION 338
9. ANONYMITY—ANONYMIZATION OF DONATION AND PROTECTION OF DATA 338
10. “BIOLOGICAL SAFETY” OF THE DONOR AND BIOBANKING 339
11. REGENERATIVE MEDICINE AND MESENCHYMAL CELLS OF THE UMBILICAL CORD AND THE PLACENTA 340
12. CONCLUSION 341
REFERENCES 342
Chapter 24 - Industrial Economics of Cord Blood Banks 344
1. TYPES OF CORD BLOOD BANKS 344
2. EMERGENCE OF HYBRID MODELS 346
3. ECONOMIC MODEL OF PUBLIC BANKS 348
4. ECONOMIC MODEL OF COMMERCIAL BANKS 350
5. ATTITUDES AND KNOWLEDGE OF PREGNANT WOMEN 352
6. COST ANALYSIS FOR PUBLIC BANKS 353
7. COST ANALYSIS FOR PRIVATE BANKS 355
8. THE EMERGENCE OF BIOINSURANCE 356
9. COST-UTILITY FOR PUBLIC HEALTH 358
10. TISSUE ECONOMIES 360
11. RETHINKING THE BUSINESS MODEL OF PRIVATE BANKS 362
REFERENCES 363
Chapter 25 - Public Health Policies in European Union: An Innovation Strategy—Horizon 2020 366
1. INTRODUCTION 367
2. THE CONFIGURATION FRAMEWORK OF GUIDING PRINCIPLES OF HEALTH POLICIES 368
3. THE HEALTH STATUS OF THE POPULATION IN THE EU 370
APPENDIX 1: EVOLUTION RATE (%) OF LIFE EXPECTANCY FOR BOTH SEXES PER DECADE (1970–2010) 371
APPENDIX 2: LIFE EXPECTANCY AT BIRTH, MALES–FEMALES (1970–2010) 371
APPENDIX 3: LIFE EXPECTANCY AT THE AGE OF 65YEARS, MALES–FEMALES (1980–2010) 372
APPENDIX 4: AGE-STANDARDIZED MORTALITY RATE (SDR-ICD-10-DISEASES OF ALL CAUSES, ALL AGES), PER 100,000 INHABITANTS 372
APPENDIX 5: BASIC CAUSES OF MORTALITY IN THE EU-28, EU-15, EU-13 (2010) 372
APPENDIX 6: CAUSES OF DEATH—STANDARDIZED DEATH RATE PER 100,000 INHABITANTS IN THE EU-28, EU-15, EU-13 (1980–2010) 372
APPENDIX 7: LOSS IN LIFE EXPECTANCY YEARS FOR MEN AND WOMEN FROM DEATH BEFORE THE AGE OF 65YEARS (1980–2010) 373
APPENDIX 8: PYLLS FROM ALL CAUSES WITH COMPARATIVE REFERENCE TO LIFE EXPECTANCY (100,000 MEN–WOMEN AGED 0–69), (1961, 2010) 373
Appendix 9: Health-adjusted Life Expectancy 373
4. REDESIGNING HEALTH POLICIES IN EUROPE 373
APPENDIX 10: THE MULTIDIMENSIONAL FIELD OF POPULATION-APPRECIATED HEALTH NEEDS 375
APPENDIX 11: MAIN OBJECTIVES OF HEALTH POLICIES: PROLONGING LIFE IN GOOD HEALTH AND WITH QUALITY YEARS 376
5. HEALTH POLICIES ON CORD BLOOD STEM CELLS BANKING 379
REFERENCES 382
Appendix 384
Index 390

Textauszug

List of Contributors

Julia Bosch,     Institute for Transplantation Diagnostics and Cell Therapeutics, University of Duesseldorf Medical School, Duesseldorf, Germany

Shijie Cai

Stem Cell Research Laboratory, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK

Weatherall Institute of Molecular Medicine, University of Oxford, UK

Lee Carpenter,     NHS Blood and Transplant and Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Keith M. Channon,     Department of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK

Dominique Charron,     Laboratoire “Jean Dausset,” Immunology and Histocompatibility Hôpital Saint-Louis AP-HP, Université Paris Diderot, Paris, France

Theofanis K. Chatzistamatiou,     Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, Athens, Greece

Audrey Cras

Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Cell Therapy Unit, Cord Blood Bank and CIC-BT501, Paris, France

INSERM UMRS 1140, Paris Descartes, Faculté de Pharmacie, Paris, France

Robert Danby

Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK

NHS Blood and Transplant, Oxford Centre, John Radcliffe Hospital, Oxford, UK

Francesco Dazzi,     Regenerative Medicine, Department of Haematology, King’s College London, London, UK

Amalia Dinou,     Hellenic Cord Blood Bank, Biomedical Research Foundation of Academy of Athens, Athens, Greece

Dominique Farge,     Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Internal Medicine and Vascular Disease Unit, CIC-BT501, Paris, France

Lydia Foeken,     World Marrow Donor Association, WMDA Office, Leiden, The Netherlands

Antonio Galleu,     Regenerative Medicine, Department of Haematology, King’s College London, London, UK

Marietta Giannakou,     MEP, Head of the Greek EPP Parliamentary Delegation, Former Minister of National Education and Religious Affairs, Former Minister of Health, Welfare and Social Security

Vasiliki Gkioka

Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Greece

Evaluation Expert, Hellenic Transplant Organization, Athens, Greece

Aspasia Goula,     Organizational Culture in Health Services, Technological Educational Institute of Athens, Greece

Gregory Katz,     ESSEC Business School, Chair of Therapeutic Innovation; Fondation Générale de Santé, Paris, France

Cheen P. Khoo

Stem Cell Research Laboratory, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK

Gesine Kögler,     Institute for Transplantation Diagnostics and Cell Therapeutics, University of Duesseldorf Medical School, Duesseldorf, Germany

George Koutitsas,     Process Analysis and Strategy Implementation Expert, National Insurance, Athens, Greece

Joanne Kurtzberg,     The Robertson Clinical and Translational Cell Therapy Program and Carolinas Cord Blood Bank, Duke University, Durham, NC USA

Paul Leeson,     Department of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK

Stefanie Liedtke,     Institute for Transplantation Diagnostics and Cell Therapeutics, University of Dusseldorf Medical School, Dusseldorf, Germany

Pascale Loiseau,     Laboratoire “Jean Dausset,” Immunology and Histocompatibility Hôpital Saint-Louis AP-HP, Université Paris Diderot, Paris, France

Daniel Markeson

Stem Cell Research Laboratory, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK

Department of Plastic and Reconstructive Surgery, Stoke Mandeville Hospital, Aylesbury, UK

University College London Centre for Nanotechnology and Regenerative Medicine, Division of Surgery and Interventional Science, Royal Free Hospital, London, UK

Elena Markogianni,     Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Greece

Emeline Masson,     Laboratoire “Jean Dausset,” Immunology and Histocompatibility Hôpital Saint-Louis AP-HP, Université Paris Diderot, Paris, France

Efstathios Michalopoulos,     Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Greece

Anna Rita Migliaccio,     Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA

Maria Mitrossili

Health Law of Technological Educational Institute of Athens, Greece

Institutional Technological Institute of Athens, Athens, Greece

Cristina Navarrete

Histocompatibility and Immunogenetic Services and NHS-Cord Blood Bank, National Blood and Transplant (NHSBT), England, UK

Division of Infection and Immunity, University College London, London, UK

Laura Newton

Stem Cell Research Laboratory, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

NHS Blood and Transplant, John Radcliffe Hospital, Oxford, UK

Department of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK

Yannis Nikolados,     Economists in Health Management, Technological Institute of Athens, Greece

Amanda L. Olson,     MD Anderson Center, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, Houston, Texas, USA

Paul J. Orchard,     Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Daniela Orsini,     World Marrow Donor Association, WMDA Office, Leiden, The Netherlands

Andreas Papassavas,     Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Greece

Thalia Papayannopoulou,     Department of Medicine/Hematology, University of Washington, Seattle, WA, USA

George Pierrakos,     Primary Health Management, Technological Educational Institute of Athens, Greece

Sergio Querol,     Barcelona Cord Blood Bank and Haematopoietic Progenitor Cell Unit, Banc Sang i Teixits, Barcelona, Spain

Teja Falk Radke,     Institute for Transplantation Diagnostics and Cell Therapeutics, University of Duesseldorf Medical School, Duesseldorf, Germany

Paolo Rebulla,     Foundation Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

Vanderson Rocha

Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK

NHS Blood and Transplant, Oxford Centre, John Radcliffe Hospital, Oxford, UK

Eurocord, Hôpital Saint Louis APHP, University Paris VII IUH, Paris, France

Marcos Sarris,     Health and Sociology and Quality of Life, Technological Educational Institute of Athens, Greece

Aurore Saudemont,     Anthony Nolan Research Institute and University College London, London, UK

Andromachi Scaradavou

National Cord Blood Program, New York Blood Center, New York, NY, USA

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Markella Serafetinidi,     Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens (BRFAA), Greece

Elizabeth J. Shpall,     MD Anderson Center, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, Houston, Texas, USA

Angela R. Smith,     Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Sotiris Soulis,     Health Economics and Social Protection, Technological Educational Institute of Athens,...

Produkt-Details

• Erscheint lt. Verlag: 3.12.2014
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete
• Themenwelt: Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung
• Themenwelt: Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
• Themenwelt: Naturwissenschaften ► Biologie ► Zellbiologie
• Themenwelt: Technik ► Umwelttechnik / Biotechnologie
• Themenwelt: Wirtschaft
• ISBN-10: 0-12-407836-2 / 0124078362
• ISBN-13: 978-0-12-407836-9 / 9780124078369